Metadata supporting data files on the impact of a hypericin PDT–tamoxifen hybrid therapy on MCF7 and MDA-MB-231 resistances
Creators: name: Theodossiou, Theodossis A.
name: Ali, Muhammad
name: Grigalavicius, Mantas
name: Grallert, Beata
name: Dillard, Pierre
name: Oliver Schink, Kay
name: Olsen, Cathrine E.
name: Wälchli, Sébastien
name: Inderberg, Else Marit
name: Kubin, Andreas
name: Peng, Qian
name: Berg, Kristian
Publisher: name: figshare
Year: 2019
Subjects: Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Chemotherapy
Cancer
Cancer Cell Biology

description: This metadata record describes the files supporting the related publication: Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy. <br>The related study reports the development of a synergistic combinatorial cancer treatment HYPERTAM, which uses tamoxifen (TAM) chemotherapy and hypericin photodynamic therapy (HYP-PDT). The study addresses the challenge of the lack of homogeneity in lesions where different cell components respond differently to treatments, a limiting factor for monotherapies.<br><b>Study design and methods</b><br>The study involved a proof of principle investigation of the efficacy of HYPERTAM in human cell culture and an in vivo animal study using NOD SCID-γ (NSG) mice.<br>The efficacy of HYPERTAM on cell lines was investigated using clonogenic assay and flow cytometric assay to elucidate the prevalent death mechanisms in the treatment groups (4-OHT, HYP-PDT and 4-OHT+HYP-PDT). The extent of lipid peroxidation in the various treatment groups in the two cell lines was then investigated, followed by metabolic analyses after HYPERTAM treatment with oxygen consumption rate (OCR) reflecting the respiratory activity of the cells, and extracellular (media) acidification rate reflecting the cell glycolytic activity.<br>Following the proof of principle investigation in cell cultures, the hypothesis that HYP-PDT exacerbates the cytotoxic action of tamoxifen by irreversibly inhibiting mitochondrial complex III<sup>25</sup> was investigated in an in-vivo pilot study. This used immunocompromised NSG mice bearing MCF7 and MDA-MB-231 xenografted tumors. Survival rates were based on the endpoints of tumor volume being ≤1000 mm<sup>3</sup>.<br><b>Sample size</b><br>Each mouse group contained at least 5 mice while the groups of particular interest contained either 6 or 7 mice. See related article for detailed group breakdown.<b><br></b><b>Software needed to access data:</b><br><b>Excel</b> files are accessible using MS Office or Open office programs, <b>.tiff</b> image files are accessible via openly available image viewing software, <b>.fcs</b> cytometer data files are accessible using FlowJo software, <b>.pzf </b>files are accessible using GraphPad Prism, <b>.scn </b>files are accessible image lab software by BioRad (note that all unprocessed blots are already appended as figs. S11,12 in the related research article), <b>.asyr </b>is a results file produced by Seahorse XF wave software.<br><b>Data access:</b><br><br>All data files are stored in Institutional file storage and available on request for non-commercial academic use only.<br>Please submit data access requests in the form of an email with names and affiliations and a brief statement of the reason for data use to:Theodossis A. Theodossiou, Department of Radiation Biology, 19 Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 20 0379 Oslo, Norway. Email: Theodossis.Theodossiou@rr-research.no<br>The animal work performed was approved on April 13 2015 with approval no. 7489by the ethical committee of the animal facility of Radium Hospital (157).<b><br></b><b>Raw data files </b><br>listed by figure/table in related article, file name and file type<br><b>Data supporting figure 1:</b> effects of HYP-PDT and 4-OHT combinatorial treatmentHYPERTAM_cumulative_MCF7_MDA-MB-231Excel<br><b>Data supporting figure 2: </b>clonogenic survival following HYPERTAMHYPERTAM_clonogenicity_dataExcel<br><b>Data supporting figure 3:</b> lipid peroxidation following HYPERTAMHYPERTAM_liperox_images.tiff<br><b>Data supporting figure 4: </b>metabolic analyses following HYPERTAMhypertam_mito stress, hypertam_mito stress-light-1min.asyr<br><b>Data supporting figure 5: </b>survival of xenograft-bearing mice following HYPERTAMSurvival data MDA-MB &amp; MCF7 UPDATE.pzf<br><b>Supplementary Figure 3:</b> clonogenic survival after HYPERTAM and ER knockdownHyperTam-clonogenic_ESRExcel<br><b>Supplementary Figure 4:</b> flow cytometry plots for cell and treatment groupsfcs<b><br></b><b>Supplementary Figure 5:</b> flow cytometry plots for cell and treatment groupsraw data files.fcs<br><b>Supplementary Figure 6: </b>effects of HYPERTAM on cell necrosisHyperTam_LDH_data.opj<br><b>Supplementary Figure 7: </b>effects of HYPERTAM on cell autophagyraw data files.scn<br><b>Supplementary Figure 8:</b> tumor growth for the different treatment groups of the MCF7 and MDA-MB-231 tumor modelsSurvival data MDA-MB &amp; MCF7 UPDATE.pzf, prism<br><b>Supplementary Figure 9: </b>mice survival vs. number of tamoxifen bolusesSurvival MCF7 4Bolus vs 2Bolus vs Control.pzf, prism<br><b>Supplementary Table 1: </b>mice survivals for the various treatment groups.Survival data MDA-MB &amp; MCF7 UPDATE.pzf, prism